U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938580) titled 'Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia' on Nov. 09.
Brief Summary: This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Myelofibrosis
Intervention:
DRUG: Gecacitinib
Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be bas...